Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.62 |
| ▸ | VCP | P55072 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CFTR | P13569 | 1/20 | 0.54 |
| ▸ | GUSB | P08236 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9645864 | 0.84 | NPC1 (0.69) | ABL1ALOX5VCPMAPTKDM4E | |
| SCHEMBL28564131 | 0.81 | NPC1 (0.70) | ABL1ALOX5VCPMAPTMEN1 | |
| SCHEMBL205976 | 0.81 | ALOX5 (0.80) | ABL1ALOX5VCPMAPTKDM4E | |
| SCHEMBL10246014 | 0.80 | ALOX5 (0.76) | ABL1ALOX5VCPMAPTKDM4E | |
| SCHEMBL474314 | 0.80 | RAB9A (0.59) | ABL1ALOX5VCPMAPTKDM4E | |
| Bromide SCHEMBL8355363 | 0.78 | RAB9A (0.57) | ABL1ALOX5VCPMAPTKDM4E | |
| SCHEMBL25735740 | 0.78 | ABL1 (1.00) | ABL1MAPTKDM4EPOLBGAA | |
| SCHEMBL5698623 | 0.78 | MEN1 (0.69) | ABL1ALOX5VCPMAPTKDM4E | |
| SCHEMBL18282016 | 0.78 | KDM4E (0.59) | ABL1ALOX5VCPMAPTKDM4E | |
| SCHEMBL5325600 | 0.77 | ALOX5 (1.00) | ABL1ALOX5VCPMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12150934-B2 | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2024-11-26 | — | — | US | disclosed |
| CN-118930533-A | Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-110603254-B | Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2024-04-12 | — | — | CN | disclosed |
| US-11602526-B2 | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto | BANTAM PHARMACEUTICAL, LLC (US) | 2023-03-14 | — | — | US | disclosed |
| US-20230076820-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2023-03-09 | — | — | US | disclosed |
| US-11325903-B2 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-11192887-B2 | — | — | 2021-12-07 | — | — | US | disclosed |
| US-20200261424-A1 | Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto | BANTAM PHARMACEUTICAL, LLC | 2020-08-20 | — | — | US | disclosed |
| US-20200069656-A1 | Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2020-03-05 | — | — | US | disclosed |
| CN-110769823-A | Methods of using substituted pyrazole and pyrrole compounds and treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20130178505-A1 | Compounds for the Inhibition of Cellular Proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178505-A1 | Compounds for the Inhibition of Cellular Proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178505-A1 | Compounds for the Inhibition of Cellular Proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-11 | — | — | US | disclosed |
| EP-2585453-A2 | COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION | President and Fellows of Harvard College (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8257931-B2 | Regulation of protein synthesis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-09-04 | — | — | US | disclosed |
| WO-2012006068-A2 | COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006068-A2 | COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20100144805-A1 | Regulation of protein synthesis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-10 | — | — | US | disclosed |
| EP-1868604-A2 | REGULATION OF PROTEIN SYNTHESIS BY INHIBITION OF EIF4E-EIF4G INTERACTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006078942-A2 | REGULATION OF PROTEIN SYNTHESIS BY INHIBITION OF EIF4E-EIF4G INTERACTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325903-B2 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | KRAS, TP53, CCNI | ABL1 327/4885ALOX5 2992/4885VCP 2802/4885 |
| US-20200261424-A1 | Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto | EIF4A1, EIF4A3, EIF4B | ABL1 1465/4885ALOX5 2803/4885VCP 3843/4885 |
| US-20100144805-A1 | Regulation of protein synthesis | EIF4EBP1, RNMT, NCBP1 | ABL1 3587/4885ALOX5 4171/4885VCP 2258/4885 |
| US-20200069656-A1 | Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases | KRAS, TP53, CCNA1 | ABL1 672/4885ALOX5 2757/4885VCP 3821/4885 |
| US-11192887-B2 | — | KRAS, TP53, CCNE1 | ABL1 243/4885ALOX5 2683/4885VCP 2846/4885 |
| US-20230076820-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | KRAS, TP53, NRAS | ABL1 343/4885ALOX5 2707/4885VCP 3103/4885 |
| US-20130178505-A1 | Compounds for the Inhibition of Cellular Proliferation | MKI67, EIF2AK2, CDK2 | ABL1 2171/4885ALOX5 2850/4885VCP 1414/4885 |
| US-12150934-B2 | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases | KRAS, TP53, CCNA1 | ABL1 672/4885ALOX5 2757/4885VCP 3821/4885 |
| US-11602526-B2 | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto | EIF4A1, EIF4A3, EIF4B | ABL1 1465/4885ALOX5 2803/4885VCP 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.